fingolimod hydrochloride has been researched along with Infections in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hartung, HP; Kleinschnitz, C; Mausberg, AK; Meyer Zu Hörste, G; Stettner, M; Szepanowski, F; Warnke, C | 1 |
| Cohen, JA; Cree, BAC; Fox, EJ; Kolodny, S; Lublin, FD; Meng, X; Williams, IM; Wolinsky, JS; Ziehn, M | 1 |
| Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Luna, G; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M | 1 |
| Boffa, G; Bruschi, N; Capello, E; Cellerino, M; Inglese, M; Lapucci, C; Novi, G; Sbragia, E; Uccelli, A | 1 |
| Dong, Y; Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK | 1 |
| Di Lecce, V; Direnzo, V; Iaffaldano, A; Iaffaldano, P; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S | 1 |
| Arnold, DL; Banwell, B; Bar-Or, A; Brück, W; Chen, Y; Chitnis, T; Gärtner, J; Ghezzi, A; Giovannoni, G; Greenberg, B; Krupp, L; Merschhemke, M; Putzki, N; Rostásy, K; Stites, T; Tardieu, M; Waubant, E; Wolinsky, JS | 1 |
| Cohen, JA; Collins, W; Francis, G; Kappos, L; Mercier, F; O'Connor, P; Tang, D | 1 |
| D'Crus, A; Enjeti, AK; Melville, K; Rowlings, P; Verrills, NM | 1 |
| East, JE; Subrahmanyam, PB; Tiper, IV; Webb, TJ | 1 |
| Brescia Morra, V; Brogi, D; Comi, G; Guidi, L; Laroni, A; Lugaresi, A; Mancardi, GL; Pozzilli, C; Raimondi, D; Turrini, R; Uccelli, A | 1 |
| Chun, J; Cohen, JA | 1 |
| Aki, FT; Kahan, BD | 1 |
| Boira, JG; Charpentier, B; Kahan, BD; Madsen, S; Mourad, G; Mulgaonkar, S; Nashan, B; Pellet, P; Tedesco-Silva, H; Vanrenterghem, Y; Weimar, W | 1 |
6 review(s) available for fingolimod hydrochloride and Infections
| Article | Year |
|---|---|
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.
Topics: Age Factors; Alemtuzumab; Animals; Coinfection; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Infections; Natalizumab; Neurology; Risk Factors; Rituximab | 2021 |
Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Infections; Multiple Sclerosis; Odds Ratio; Publication Bias; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2021 |
A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Fingolimod Hydrochloride; Humans; Infections; Leukemia, Myeloid, Acute; Observational Studies as Topic | 2016 |
Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.
Topics: Animals; Chemotaxis, Leukocyte; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Hematologic Neoplasms; Host-Pathogen Interactions; Humans; Immune System; Immunosuppressive Agents; Infections; Inflammation; Lymphocytes; Lysophospholipids; Signal Transduction; Sphingosine; Transcription Factors | 2016 |
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Topics: Animals; Central Nervous System; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Heart Diseases; Humans; Immunosuppressive Agents; Infections; Liver Diseases; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Respiration Disorders; Sphingosine | 2011 |
FTY720: A new kid on the block for transplant immunosuppression.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dogs; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Mice; Primates; Propylene Glycols; Rats; Reperfusion Injury; Sphingosine; Transplantation Immunology; Transplantation, Heterologous | 2003 |
5 trial(s) available for fingolimod hydrochloride and Infections
| Article | Year |
|---|---|
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.
Topics: Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Infections; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Time Factors | 2019 |
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Topics: Administration, Oral; Adolescent; Brain; Child; Female; Fingolimod Hydrochloride; Headache; Humans; Immunologic Factors; Infections; Injections, Intramuscular; Interferon-beta; Leukopenia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention | 2018 |
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infections; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Topics: Adult; Female; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Infections; Italy; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2017 |
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Topics: Adolescent; Adult; Aged; Biopsy; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Middle Aged; Mycophenolic Acid; Postoperative Complications; Propylene Glycols; Safety; Sphingosine; Time Factors; Treatment Outcome | 2005 |
3 other study(ies) available for fingolimod hydrochloride and Infections
| Article | Year |
|---|---|
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Infections; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Rituximab; Sweden | 2020 |
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Topics: Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Infections; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Multiple Sclerosis; Recurrence; Retrospective Studies; Risk | 2020 |
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.
Topics: Adult; Cell Movement; Cohort Studies; Drug Monitoring; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infections; Italy; Liver Function Tests; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Risk Assessment; Secondary Prevention; Sex Factors | 2017 |